The Pompe Disease Therapeutic Market can be divided into four categories based on the type of treatment used: supportive care, chaperone-advanced replacement therapy (CART), substrate reduction therapy (SRT), and enzyme replacement therapy (ERT). The only long-term treatments for the condition are Genzyme's ERT treatments Myozyme and Lumizyme, which were approved for the treatment of paediatric and adult-onset Pompe disease, respectively, in 2006 and 2010.
North America is one of the top markets globally, and this tendency is anticipated to last. Asia Pacific (APAC) is anticipated to have rapid expansion over the course of the forecast period, driven by rising patient awareness of rare illnesses and improving healthcare infrastructure in APAC nations.
